BG Medicine Re-Files for IPO

BG Medicine Inc., a Waltham, Mass.-based developer of molecular diagnostics based on biomarkers, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol BGMD, with Jefferies & Co. and UBS serving as co-lead underwriters. The company previously filed for a $72 million IPO in 2007 with Cowen & Co. as lead underwriter, but later pulled the offering due to “unfavorable market conditions.”

BG Medicine has raised over $37 million in VC funding since 2000, from firms like Flagship Ventures (44.4% pre-IPO stake), Gilde Investment Management (14.1%) and Koniklijke Philips Electronics (5.6%).